Focus on Lipids Care

Back to articles

Rosuvastatin: Newest HMG-CoA Reductase Inhibitor a ‘Super’ Selection

KEY POINT

The first “superstatin” is headed to the U.S. market, thanks to FDA’s August approval of rosuvastatin (Crestor—AstraZeneca). The potent medication could become an agent of first choice for treating patients who need aggressive lipid lowering, if concerns about renal toxicities can be allayed.

SOURCES

Crestor Web site. http://www.crestor.com